Tertiapin LQ

Product Name: Tertiapin LQ

Purity: 95%

Molar Mass: 2428.0

Chemical Formula: C106H179N33O24S4

Storage: Store at -20 degree Celsius

Sequence: ALCNCNRIIIPLQCWKKCGKK

Application: Tertiapin LQ is a peptide toxin derived from honey bee venom, specifically designed to block inward rectifier potassium (Kir) channels, particularly Kir1.1 and Kir3.1/3.4. By inhibiting these channels, Tertiapin LQ modulates cellular excitability and ion transport. It is extensively used in cardiovascular and renal research to study the roles of Kir channels in heart rhythm regulation, renal function, and insulin secretion. Additionally, Tertiapin LQ has potential applications in developing therapeutic agents for cardiac arrhythmias, hypertension, and other conditions involving dysfunctional potassium channel activity.

Current Research:

Tertiapin LQ is a synthetic peptide derivative of tertiapin, originally isolated from honeybee venom. It functions as a potent and selective inhibitor of specific inwardly rectifying potassium (Kir) channels, notably the G protein-coupled inward rectifier potassium channels (GIRK1/4) and the renal outer medullary potassium channel (ROMK1, Kir1.1). The enhanced stability of Tertiapin LQ, achieved through targeted modifications, makes it a valuable tool in electrophysiological studies and potential therapeutic applications.
In cardiovascular research, Tertiapin LQ has been instrumental in elucidating the role of GIRK channels in cardiac physiology. By inhibiting these channels, Tertiapin LQ has been shown to modulate heart rate and atrioventricular conduction, providing insights into arrhythmogenic mechanisms and potential therapeutic targets for cardiac dysfunctions.
In the field of neuroscience, Tertiapin LQ has been utilized to study neuronal excitability and synaptic transmission. Its ability to block specific Kir channels has shed light on the regulation of neuronal firing patterns and the maintenance of resting membrane potentials, contributing to a deeper understanding of neural network dynamics and potential interventions for neurological disorders.
Additionally, Tertiapin LQ has been employed in renal physiology to investigate the function of ROMK1 channels in potassium homeostasis. By selectively inhibiting these channels, researchers have gained insights into renal potassium handling and its implications in conditions such as hyperkalemia and hypertension.
The specificity and potency of Tertiapin LQ in targeting Kir channels underscore its significance in biomedical research. Its applications extend to the development of novel therapeutic strategies for cardiovascular, neurological, and renal disorders where Kir channel dysfunction is implicated.
In summary, Tertiapin LQ serves as a crucial molecular tool in the study of inwardly rectifying potassium channels, offering valuable insights into their physiological roles and potential as therapeutic targets. Ongoing research continues to explore its applications across various domains of health and disease.

Reference: Okada, M., Kozaki, I., & Honda, H. (2020). Antidepressive effect of an inward rectifier K+ channel blocker peptide, tertiapin-RQ. Plos one, 15(11), e0233815.